#3620
Real-world SEER-Medicare data analysis of the evolution of tumor characteristics, first-line therapies and overall survival (OS) in patients with neuroendocrine tumors (NETs)
Introduction:
Recent data on NET therapy utilization and impact in real-world practice are scarce.
Conference:
Presenting Author:
Authors:
Schneider M,
Sinha A,
Dasari A,
Chan J,
Stoffels A,
Keywords:
neuroendocrine tumor,
NET characteristics,
first-line therapy,
treatment evolution,
treatment patterns,
overall survival,
#1003
Signalling Pathways in Bronchial Neuroendocrine Tumor Disease and Its Translation to Innovative Targets: The New Kid on the Block
Introduction:
Bronchial neuroendocrine neoplasias comprise a wide spectrum of well-differentiated tumors (typical/atypical carcinoids) to undifferentiated carcinomas such as small (SCLC) and large cell (LC) neuroendocrine carcinomas with a fatal prognosis. Therapeutic options are unsatisfactory.
Conference:
11th Annual ENETSConcerence (2014)
Presenting Author:
Lewens F
Authors:
Lewens F,
Freitag H,
Briest F,
Heilmann M,
Schneider C,
Keywords:
bronchial,
NETs,
PI3K,
FoxM1,
survivin,
cell lines,
SCLC,
#29
Serum chromogranin A correlation with tumor burden in metastatic small bowel carcinoid patients
Introduction:
Patients with neuroendocrine tumors may have clinical courses that range from fairly indolent to more aggressive. Cross–sectional studies, nuclear imaging and biochemical markers are often used to monitor disease progression. Optimal surveillance tests and intervals have not been firmly established. Studies suggest that chromogranin A (CgA) may be a surrogate marker for tumor burden.
Conference:
7th Annual ENETSConcerence (2010)
Presenting Author:
Curran T
Authors:
Schneiderman M,
Curran T,
Lee K,
Warner R,
Kim M,
Keywords:
carcinoid,
metastatic,
biomarkers,
radiology,
chromogranin A,
#28
Prognostic Clinicopathologic Factors in Longitudinally Followed Patients with Metastatic Small Bowel Carcinoid
Introduction:
Neuroendocrine tumors demonstrate heterogeneous behavior based upon site of origin and specific histology. Even after controlling for anatomic location, disease stage and histologic grade, registry studies show persistent diversity of outcome in patients with midgut carcinoid.
Conference:
7th Annual ENETSConcerence (2010)
Presenting Author:
Authors:
Curran T,
Serbowicz S,
Patel K,
Schneiderman M,
Ward S,
Keywords:
carcinoid. small bowel,
metastatic,
chromogranin-A,
